Navigating a Dynamic Treatment Landscape: Established Therapies and Emerging Modalities for Patients with Lung Cancer

This video has been supported and provided by Bristol Myers Squibb.

These slides are intended for educational use. The content within may refer to treatment, indications or uses not approved by your local regulatory agency in your home country. Please always refer to your local prescribing information. Bristol Myers Squibb does not endorse the promotion of unapproved products or indications. 

The views expressed in this presentation are those of the presenters. 

This material is not to be distributed outside of this meeting. 

Juergens has received advisory board/lecture fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Glaxo Smith Klein, Janssen, Eli Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda; and research funding from Alkermes, Amgen, Astellas, AstraZeneca, Bold Therapeutics, Bristol Myers Squibb, Conjupro, Janssen, Merck Sharp & Dohme, Pfizer, and SignalChem. 

Jänne has served as a consultant/advisor for AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly, SFJ Pharmaceuticals, Voronoi, Daiichi Sankyo, Biocartis, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Eisai, Allorion Therapeutics, Accutar Biotech, Abbvie, Monte Rosa Therapeutics, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, Duality Biologics, Blueprint Medicines, Dizal Pharma, GlaxoSmithKline, Tolremo, Myris Therapeutics, and Bristol Myers Squibb; research funding from AstraZenenca, Daiichi Sankyo, PUMA, Eli Lilly, Boehringer Ingelheim, Revolution Medicines, Takeda Oncology, and Troper Wojcicki Foundation, with payments to institution; and post-marketing royalties from Dana Farber Cancer Institute owned intellectual property on EGFR mutations licensed to Lab Corp. 

Heymach has received advisory board/lecture fees from AbbVie, Abdera Therapeutics, Amgen, AnHeart Therapeutics, Arrivent, AstraZeneca, BioNTech AG, Boehringer-Ingelheim, Bristol Myers Squibb, Curio Science, DAVA Oncology, Eli Lily & Co, EMD Serono, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Mirati Therapeutics, Moffitt Cancer Center, ModeX, Novartis Pharmaceuticals, OncoCyte, Pfizer, Regeneron, Sanofi, Spectrum Pharmaceuticals, and Takeda; research funding from AstraZeneca, Boehringer-Ingelheim, Mirati, Bristol-Myers Squibb, and Takeda; and licensing/royalties from Spectrum Pharmaceuticals. 

In this symposium, Rosalyn Juergens, Pasi Jänne, and John Heymach focused on patient-centric approaches to mNSCLC treatment.

The session highlighted the importance of making informed, optimal treatment decisions for patients with PD-L1 <1% mNSCLC, particularly with the use of I-O–based regimens. The expert faculty panel delved into the growing momentum of targeted-therapy research for patients with KRAS G12C-mutated NSCLC, focusing on agents both approved and in development. The session concluded with a spotlight on ongoing research and innovation for novel treatment options and modalities aimed at meeting the diverse and complex needs of patients across the lung-cancer spectrum.

1. Medical Oncology, Juravinski Cancer Centre, Ontario, Canada
2. Medical Oncology, Dana-Farber Cancer Institute, Massachusetts, USA
3. Medical Oncology, Anderson Cancer Center, Texas, USA